oyikey smgt glp 1 nano microneedle patch reviews directions glp 1 microneedle patches SMGT-GLP-1 Nano Oyikey SMGT GLP-1 Microneedle Patch

Previous studies have shown that the presence of stress, hyperglycemia or diabetes is detrimental to the outcome of ischemic stroke and is associated with higher degrees of hemorrhagic transformation [52, 53]

When appetite is chemically reduced, some patients report feeling less pleasure from food and, by extension, experience a generalized dampening of hedonic responses

The appetite suppression these drugs create makes it difficult to eat enough protein to preserve muscle mass, and roughly 25% of weight lost on GLP-1 drugs comes from lean tissue on average, with some trials reporting up to 40%

One major concern is the skyrocketing price of GLP-1 medications

Back in 2018, most of its earnings came from generics, with only a small share driven by innovation. Between 2025 and 2027, the company expects to bring dozens of major breakthroughs to market from GLP-1 therapies for obesity and diabetes to next-generation oncology treatments. Source: *Opinions are my own To view or add a comment, sign in Big Pharma News: Pfizer is set to acquire Metsera in a deal worth up to $4.9B Why it matters: $47.50/share upfront + $22.50/share tied to milestones Lead candidate MET-097i (GLP-1 therapy) showed 11.3% weight loss in 12 weeks Pipeline includes monthly amylin-based injections + oral obesity drugs Puts Pfizer head-to-head with Lilly & Novo Nordisk in the obesity race This move highlights the booming obesity drug market and pharmas growing appetite for metabolic innovation

I believe the market was uniquely slow to recognize the potential of GLP-1s for several reasons specific to this drug class